Centro de Medicina de Reabilitação de Alcoitão
Alcabideche, Lisbon District, 2649-506, Portugal
Location status: Recruiting
NCT Number: NCT07374276
The goal of this clinical trial is to investigate if training sessions of motor imagery associated with brain-computer interface and motor observation through virtual reality (MI-VR-BCI) can help to improve arm and hand recovery after a stroke. The main questions to answer are:
* Can adding MI-BCI-VR sessions improve upper limb movement? * Can it help stroke survivors perform daily activities more easily? * Does this type of training improve brain activity and connections related to movement?
Researchers will compare this type of intervention with motor imagery associated with a standard brain-computer interface intervention (MI-BCI) to see if there are added effects to upper limb function, activity and brain connections.
Participants will :
* Perform two intervention periods in a random order: one with MI-VR-BCI training sessions and other with MI-BCI training sessions. Each period will involve 3 weekly sessions of training, during 6 weeks, with the intervention periods being separated by 3 weeks. * Complete four assessment sessions: one at the beginning and another at the end of each intervention period.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Not applicable
Alcabideche, Lisbon District, 2649-506, Portugal
Location status: Recruiting
Stroke is a leading cause of long-term disability worldwide, often resulting in upper limb (UL) impairment. Approximately 70% of stroke survivors experience UL dysfunction, with a significant portion continuing to show deficits into the chronic phase. This impacts independence and quality of life, highlighting the need for effective rehabilitation strategies.
Brain-Computer Interface (BCI) interventions have shown promise in improving UL function by enabling patients to modulate brain activity through neurofeedback in a closed-loop system. When combined with multisensory feedback (visual, auditory, and somatosensory) BCIs may promote neuroplasticity and motor recovery. The use of Motor Imagery (MI) and embodied Virtual Reality (VR) may further enhance motor learning by reinforcing motor patterns and creating meaningful, immersive rehabilitation experiences.
Despite encouraging evidence, the clinical and neurophysiological benefits of combining BCI with VR and MI remain underexplored, particularly when associated with longer intervention periods, the impact in activities of daily living and the influence of patient-specific traits such as motor, cognitive, or behavioral dimensions. In light of these considerations, the primary objectives of this study are:
The secondary objectives of the study are:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The training paradigm will involve motor imagery coupled with EEG-based BCI control and immersive virtual reality (VR) feedback. VR feedback will consist of NeuRow, a first-person perspective training paradigm that allows multimodal visual, auditory and haptic feedback through the use of immersive virtual reality headset and haptic controllers. Sessions will have a frequency of 3 times per week, during 6 weeks.
The training paradigm will involve motor imagery combined with EEG-based BCI control using a cue-based visual paradigm. Sessions will be conducted three times per week over a period of six weeks.
Time frame: Baseline and end of each 6-week intervention period (up to 15 weeks total, including washout).
Within-subject difference in the change in upper limb motor function, as assessed by the Fugl-Meyer Assessment for the Upper Extremity (FMA-UE), between the two intervention conditions (MI-BCI-VR vs. MI-BCI). FMA-UE scores range from 0 to 66, with higher scores indicating better motor function and less impairment.
Time frame: Baseline and end of each 6-week intervention period (up to 15 weeks total, including washout).
Within-subject difference in the change in upper limb activity, as assessed by the Action Research Arm Test (ARAT), between the two intervention conditions (MI-BCI-VR vs. MI-BCI). The ARAT is a standardized measure that evaluates upper limb functioning through tasks involving grasp, grip, pinch, and gross movement. Scores range from 0 to 57, with higher scores indicating better functional ability. This outcome assesses the impact of the intervention on functional use of the affected arm in daily activities.
Time frame: During each intervention session across both 6-week intervention periods (up to 15 weeks total, including washout).
Changes in event-related desynchronization and synchronization (ERD/ERS) during motor imagery tasks, derived from EEG recordings to assess intervention-related modulation of sensorimotor cortical activity.
Time frame: During each intervention session across both 6-week intervention periods (up to 15 weeks total, including washout).
Changes in EEG-derived hemispheric lateralization indices during motor imagery tasks, used to evaluate intervention-related reorganization of cortical motor networks.
Time frame: During each intervention session across both 6-week intervention periods (up to 15 weeks total, including washout).
Exploratory changes in EEG-based functional connectivity metrics between motor-related cortical regions during motor imagery tasks.
Time frame: Baseline and end of each 6-week intervention period (up to 15 weeks total, including washout).
Cognitive function will be assessed using the MoCA to characterize participants' baseline function, explore potential changes associated with the intervention, and examine its role as a predictor or moderator of rehabilitation outcomes. The MoCA is a brief cognitive screening tool designed to assess multiple cognitive domains with a score ranging from 0 to 30, with higher scores reflecting better cognitive performance.
Time frame: Baseline and end of each 6-week intervention period (up to 15 weeks total, including washout).
Stroke-related participation and quality of life, as measured by the SIS 2.0, will be used to characterize participants' baseline function, explore potential changes associated with the intervention, and examine its role as a predictor or moderator of rehabilitation outcomes. The SIS is a self-report questionnaire designed to assess the impact of stroke across multiple domains, including strength, hand function, mobility, communication, memory, emotion, activities of daily living (ADL), and social participation. Higher scores indicate better perceived recovery and participation.
Time frame: Baseline and end of each 6-week intervention period (up to 15 weeks total, including washout).
Depressive symptoms will be assessed using the PHQ-9 to characterize participants' baseline function and explore their potential role as a predictor or moderator of rehabilitation outcomes. PHQ-9 is a self-report questionnaire with 9 items used to screen for and measure the severity of depressive symptoms. Each item is rated on a 4-point scale (0-3), with higher total scores indicating greater depressive symptomatology.
Time frame: Baseline and end of each 6-week intervention period (up to 15 weeks total, including washout).
Spatial Neglect will be screened using the Bells Test to characterize participants' baseline function, explore potential changes associated with the intervention, and examine its role as a predictor or moderator of rehabilitation outcomes. The Bells Test is a paper-and-pencil cancellation task allowing the evaluation of egocentric neglect in peripersonal space through the analysis of the number and spatial distribution of omissions
Time frame: Baseline and end of each 6-week intervention period (up to 15 weeks total, including washout).
Spasticity in the upper limb will be assessed using the MAS to describe muscle tone at baseline, to explore potential changes associated with the intervention, and examine its role as a predictor or moderator of rehabilitation outcomes. The MAS is a 6-point ordinal scale ranging from 0 to 4, with higher scores indicating greater spasticity levels.
Time frame: Immediately after completion of each 6-week intervention period (2 assessment points per participant).
Participants' experience with the intervention and interaction with the technology will be quantitatively assessed using a questionnaire developed by the research team, covering multiple dimensions (setup, session experience, visual scenario and interaction, task execution, gamification and feedback, and potential adverse effects). The instrument includes 5-point Likert scale items and visual analogue scale components.
Time frame: After completion of both intervention periods (end of study).
Participants' subjective experiences, perceived usability, clinical relevance, challenges, preferences, and suggestions regarding the intervention paradigms will be qualitatively explored, through a semi-structured interview. Data will be analyzed using reflexive thematic analysis to identify recurring themes and insights.
Contact information is provided by the study sponsor or research team.
Technical University of Lisbon
Other
Brain-Computer Interface (BCI) With Virtual Reality (VR) in Upper Limb Rehabilitation After Stroke: A Randomized Crossover Clinical Trial
Acronym: NOISyS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06615973
Brain Disease, Brain Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT05378035
Arrhythmias, Cardiac, Arterial Thromboembolism
Hong Kong
View Trial DetailsNCT03821129
Brain Diseases, Cardiovascular Abnormalities
Tucson, Arizona, United States
View Trial DetailsNCT07737431
Brain Diseases, Cardiovascular Diseases
Hung Hom, Kowloon, Hong Kong
View Trial Details